FDA Grants New Indication for Tecentriq Plus Cotellic and Zelboraf for Advanced Melanoma

By PPN News Staff
The FDA granted a new indication for atezolizumab (Tecentriq, Genentech) to be used with cobimetinib (Cotellic, Genentech) and vemurafenib (Zelboraf, Genentech) to treat patients with BRAF V600 mutation–positive advanced melanoma.